ANZ DATA

AUSTRALIA & NEW ZEALAND
DIALYSIS & TRANSPLANT REGISTRY

MISSING DATA REPORT

Survey Data 2012 - 2016

Abstract

The rates of non-response for ANZDATA
survey items over the last 5 years

anzdata@anzdata.org.au

www.anzdata.org.au

ANZDATA Missing Data Report

The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2012	2013	2014	2015	2016
Frequency	3147	3187	3332	3296	3389
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	40 (1.3%)	39 (1.2%)	51 (1.5%)	81 (2.5%)	127 (3.7%)
Late referral seen <3 mths before 1st treatment	54 (1.7%)	32 (1.0%)	73 (2.2%)	142 (4.3%)	170 (5.0%)
Racial origin	34 (1.1%)	23 (0.7%)	62 (1.9%)	106 (3.2%)	191 (5.6%)
Primary renal disease	5 (0.2%)	8 (0.3%)	28 (0.8%)	126 (3.8%)	175 (5.2%)
Was native kidney biopsied?	45 (1.4%)	42 (1.3%)	83 (2.5%)	144 (4.4%)	265 (7.8%)
Serum creatinine at entry	56 (1.8%)	34 (1.1%)	80 (2.4%)	138 (4.2%)	163 (4.8%)
Height at RRT entry (cm)	59 (1.9%)	42 (1.3%)	103 (3.1%)	145 (4.4%)	228 (6.7%)
Weight at RRT entry (kg)	29 (0.9%)	24 (0.8%)	46 (1.4%)	74 (2.2%)	139 (4.1%)
Smoking status at RRT entry	41 (1.3%)	22 (0.7%)	13 (0.4%)	141 (4.3%)	209 (6.2%)

Table 2 Comorbidities at RRT entry

Variable	2012	2013	2014	2015	2016
Frequency	3147	3187	3332	3296	3389
Postcode	517 (16.4%)	547 (17.2%)	532 (16.0%)	415 (12.6%)	218 (6.4%)
Chronic lung disease	7 (0.2%)	7 (0.2%)	19 (0.6%)	58 (1.8%)	122 (3.6%)
Coronary artery disease	7 (0.2%)	7 (0.2%)	19 (0.6%)	59 (1.8%)	120 (3.5%)
Peripheral vascular disease	7 (0.2%)	7 (0.2%)	19 (0.6%)	60 (1.8%)	121 (3.6%)
Cerebrovascular disease	7 (0.2%)	7 (0.2%)	19 (0.6%)	61 (1.9%)	121 (3.6%)
Diabetes	7 (0.2%)	7 (0.2%)	16 (0.5%)	48 (1.5%)	111 (3.3%)

Table 3 Comorbidities at survey date

Variable	2012	2013	2014	2015	2016
Frequency	27571	28676	29793	30771	31732
Postcode	4599 (16.7%)	4769 (16.6%)	4924 (16.5%)	3122 (10.1%)	1231 (3.9%)
Chronic lung disease	61 (0.2%)	68 (0.2%)	89 (0.3%)	177 (0.6%)	224 (0.7%)
Coronary artery disease	58 (0.2%)	66 (0.2%)	86 (0.3%)	176 (0.6%)	228 (0.7%)
Peripheral vascular disease	59 (0.2%)	67 (0.2%)	88 (0.3%)	176 (0.6%)	226 (0.7%)
Cerebrovascular disease	61 (0.2%)	69 (0.2%)	89 (0.3%)	179 (0.6%)	231 (0.7%)
Diabetes	61 (0.2%)	70 (0.2%)	94 (0.3%)	192 (0.6%)	226 (0.7%)
Hepatitis C Antibody	37 (0.1%)	51 (0.2%)	80 (0.3%)	224 (0.7%)	453 (1.4%)

Table 4 Reason for change from CAPD to APD

Variable	2012	2013	2014	2015	2016
Frequency	616	611	658	698	570
Reason transfer from dialysis during survey	56 (9.1%)	62 (10.1%)	49 (7.4%)	61 (8.7%)	82 (14.4%)

Table 5 Reason for change from APD to CAPD

Variable	2012	2013	2014	2015	2016
Frequency	132	135	114	126	117
Reason transfer from dialysis during survey	18 (13.6%)	15 (11.1%)	10 (8.8%)	14 (11.1%)	25 (21.4%)

Table 6 Reason for change from PD to HD

Variable	2012	2013	2014	2015	2016
Frequency	745	755	730	840	816
Reason transfer from dialysis during survey	75 (10.1%)	41 (5.4%)	51 (7.0%)	81 (9.6%)	114 (14.0%)

Table 7 Reason for change from HD to PD

Variable	2012	2013	2014	2015	2016
Frequency	631	599	582	550	516
Reason transfer from dialysis during survey	80 (12.7%)	36 (6.0%)	49 (8.4%)	54 (9.8%)	92 (17.8%)

Table 8 Cause of death

Variable	2012	2013	2014	2015	2016
Frequency	2094	2224	2295	2416	2430
Cause of death	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 9 Dialysis data

Variable	2012	2013	2014	2015	2016
Frequency	16818	17387	17980	18434	18804
Dialysis type	235 (1.4%)	163 (0.9%)	257 (1.4%)	188 (1.0%)	4 (0.0%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	530 (3.2%)	367 (2.1%)	756 (4.2%)	1080 (5.9%)	1604 (8.5%)
Uncorrected calcium levels (mmol/l)	490 (2.9%)	406 (2.3%)	677 (3.8%)	1049 (5.7%)	1472 (7.8%)
Phosphate levels (mmol/l)	476 (2.8%)	392 (2.3%)	612 (3.4%)	989 (5.4%)	1445 (7.7%)
Haemoglobin level nearest end Survey (g/l)	471 (2.8%)	407 (2.3%)	601 (3.3%)	982 (5.3%)	1440 (7.7%)
EPO Agent	493 (2.9%)	394 (2.3%)	591 (3.3%)	962 (5.2%)	1484 (7.9%)
Ferritin within last 3 months of Survey	1280 (7.6%)	1374 (7.9%)	1550 (8.6%)	1801 (9.8%)	2566 (13.6%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	1649 (9.8%)	1861 (10.7%)	2068 (11.5%)	2294 (12.4%)	3199 (17.0%)

Table 10 Haemodialysis data

Variable	2012	2013	2014	2015	2016
Frequency	13669	14047	14423	14797	15174
Dialyser brand, model, membrane, surface area	530 (3.9%)	293 (2.1%)	574 (4.0%)	877 (5.9%)	942 (6.2%)
Blood flow rate (mls/min)	466 (3.4%)	286 (2.0%)	585 (4.1%)	875 (5.9%)	1278 (8.4%)
Frequency of dialysis per week	439 (3.2%)	282 (2.0%)	563 (3.9%)	859 (5.8%)	1252 (8.3%)
Hours per session	463 (3.4%)	283 (2.0%)	567 (3.9%)	863 (5.8%)	1275 (8.4%)
Adequacy method (urea reduction or Kt/V)	2519 (18.4%)	2360 (16.8%)	2553 (17.7%)	2726 (18.4%)	3410 (22.5%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	2507 (18.3%)	2372 (16.9%)	2655 (18.4%)	2759 (18.6%)	3289 (21.7%)
Vascular access in use at last haemodialysis	401 (2.9%)	279 (2.0%)	616 (4.3%)	943 (6.4%)	1320 (8.7%)

Table 11 Access at first HD

Variable	2012	2013	2014	2015	2016
Frequency	2633	2628	2663	2699	2798
Vascular access in use at first haemodialysis	100 (3.8%)	85 (3.2%)	154 (5.8%)	279 (10.3%)	310 (11.1%)

Table 12 Peritoneal dialysis data

Variable	2012	2013	2014	2015	2016
Frequency	4245	4411	4626	4765	4743
Type of Peritoneal Connection System	117 (2.8%)	141 (3.2%)	213 (4.6%)	394 (8.3%)	403 (8.5%)
Total volume weekly exchanges - All PD	101 (2.4%)	150 (3.4%)	218 (4.7%)	365 (7.7%)	588 (12.4%)
PD Solution Glucose	80 (1.9%)	137 (3.1%)	198 (4.3%)	348 (7.3%)	459 (9.7%)
PD Solution Iodextrin	80 (1.9%)	137 (3.1%)	201 (4.3%)	354 (7.4%)	458 (9.7%)
PD Solution Low GDP (either Lactate or Bicarbonate)	80 (1.9%)	137 (3.1%)	207 (4.5%)	369 (7.7%)	457 (9.6%)
Creatinine Clearance (litres per week)	1182 (27.8%)	1264 (28.7%)	1397 (30.2%)	1643 (34.5%)	1775 (37.4%)
Dialysate Only Weekly Kt/V value on PD	1180 (27.8%)	1263 (28.6%)	1402 (30.3%)	1645 (34.5%)	1778 (37.5%)
Residual renal function (creatinine clearance - GFR)	1208 (28.5%)	1294 (29.3%)	1440 (31.1%)	1701 (35.7%)	1812 (38.2%)

Table 13 Peritoneal dialysis PET test

Variable	2012	2013	2014	2015	2016
Frequency	1286	1281	1381	1352	1346
PET test for PD-within first 6 mths starting?	635 (49.4%)	548 (42.8%)	1164 (84.3%)	1253 (92.7%)	1233 (91.6%)

Table 14 Peritonitis episodes data

Variable	2012	2013	2014	2015	2016
Frequency	1066	1173	1112	1102	1008
Was this a relapse or recurrence of peritonitis?	164 (15.4%)	170 (14.5%)	191 (17.2%)	57 (5.2%)	71 (7.0%)
Technique at time of infection	166 (15.6%)	172 (14.7%)	189 (17.0%)	17 (1.5%)	6 (0.6%)
Most recent type of training?	187 (17.5%)	184 (15.7%)	221 (19.9%)	335 (30.4%)	464 (46.0%)
Antifungal Therapy?	180 (16.9%)	180 (15.3%)	224 (20.1%)	90 (8.2%)	102 (10.1%)
Name of initial regimen first antibiotic given	164 (15.4%)	164 (14.0%)	186 (16.7%)	65 (5.9%)	63 (6.3%)
Name of final regimen first antibiotic given	195 (18.3%)	211 (18.0%)	235 (21.1%)	98 (8.9%)	130 (12.9%)
Glucose PD Solution at time of infection?	178 (16.7%)	185 (15.8%)	210 (18.9%)	129 (11.7%)	120 (11.9%)
Icodextrin PD Solution at time of infection?	179 (16.8%)	188 (16.0%)	221 (19.9%)	134 (12.2%)	130 (12.9%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	183 (17.2%)	193 (16.5%)	227 (20.4%)	111 (10.1%)	117 (11.6%)
Was patient hospitalised overnight?	171 (16.0%)	174 (14.8%)	203 (18.3%)	71 (6.4%)	72 (7.1%)
Was catheter removed?	171 (16.0%)	171 (14.6%)	190 (17.1%)	62 (5.6%)	79 (7.8%)
Did patient have interim haemodialysis?	180 (16.9%)	185 (15.8%)	207 (18.6%)	75 (6.8%)	90 (8.9%)
Did patient transfer to permanent haemodialysis?	185 (17.4%)	186 (15.9%)	202 (18.2%)	70 (6.4%)	89 (8.8%)

Table 15 Transplant baseline data

Variable	2012	2013	2014	2015	2016
Frequency	953	999	1041	1092	1257
Recipient CMV antibody status	25 (2.6%)	21 (2.1%)	42 (4.0%)	56 (5.1%)	181 (14.4%)
Recipient EBV antibody status	23 (2.4%)	22 (2.2%)	45 (4.3%)	62 (5.7%)	190 (15.1%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	39 (4.1%)	27 (2.7%)	72 (6.9%)	72 (6.6%)	205 (16.3%)
Immediate function	15 (1.6%)	19 (1.9%)	39 (3.7%)	46 (4.2%)	177 (14.1%)
HLA-A mismatch	37 (3.9%)	25 (2.5%)	35 (3.4%)	23 (2.1%)	24 (1.9%)
HLA-B mismatch	37 (3.9%)	27 (2.7%)	35 (3.4%)	22 (2.0%)	24 (1.9%)
HLA-DR mismatch	37 (3.9%)	37 (3.7%)	37 (3.6%)	22 (2.0%)	24 (1.9%)
HLA-DQ mismatch	752 (78.9%)	783 (78.4%)	691 (66.4%)	583 (53.4%)	568 (45.2%)
Donor blood group	28 (2.9%)	23 (2.3%)	38 (3.7%)	22 (2.0%)	31 (2.5%)
Recipient blood group	17 (1.8%)	12 (1.2%)	11 (1.1%)	21 (1.9%)	33 (2.6%)
Maximum cytotoxic antibodies	35 (3.7%)	145 (14.5%)	182 (17.5%)	177 (16.2%)	250 (19.9%)
Current (At transplant) antibodies	35 (3.7%)	188 (18.8%)	76 (7.3%)	72 (6.6%)	86 (6.8%)

Table 16 Cause of graft failure

Variable	2012	2013	2014	2015	2016
Frequency	288	259	289	312	285
Cause of graft failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 17 Rejection data

Variable	2012	2013	2014	2015	2016
Frequency	425	421	469	478	414
Was a biopsy performed?	11 (2.6%)	10 (2.4%)	13 (2.8%)	9 (1.9%)	1 (0.2%)
Response of this rejection to treatment	13 (3.1%)	13 (3.1%)	19 (4.1%)	20 (4.2%)	16 (3.9%)
Primary treatment of rejection	7 (1.6%)	5 (1.2%)	6 (1.3%)	6 (1.3%)	72 (17.4%)

Table 18 Rejection data if biopsy performed

Variable	2012	2013	2014	2015	2016
Frequency	404	401	446	460	401
If biopsy is Yes? Cellular	37 (9.2%)	39 (9.7%)	30 (6.7%)	4 (0.9%)	7 (1.7%)
If biopsy is Yes? Glomerular	47 (11.6%)	43 (10.7%)	46 (10.3%)	8 (1.7%)	11 (2.7%)
If biopsy is Yes? Vascular	45 (11.1%)	46 (11.5%)	43 (9.6%)	7 (1.5%)	15 (3.7%)
Humoral Rejection	55 (13.6%)	41 (10.2%)	53 (11.9%)	14 (3.0%)	17 (4.2%)
If biopsy is Yes and Banff g is known	96 (23.8%)	60 (15.0%)	66 (14.8%)	57 (12.4%)	59 (14.7%)
If biopsy is Yes and Banff i is known	95 (23.5%)	60 (15.0%)	66 (14.8%)	57 (12.4%)	54 (13.5%)
If biopsy is Yes and Banff t is known	97 (24.0%)	60 (15.0%)	65 (14.6%)	56 (12.2%)	54 (13.5%)
If biopsy is Yes and Banff v is known	98 (24.3%)	61 (15.2%)	67 (15.0%)	59 (12.8%)	61 (15.2%)

Table 19 Rejection data if biopsy not performed

Variable	2012	2013	2014	2015	2016
Frequency	10	10	10	9	12
Likelihood of rejection if biopsy not performed	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)	1 (8.3%)

Table 20 Transplant follow-up data, 0 months

Variable	2012	2013	2014	2015	2016
Frequency	962	1009	1059	1108	1271
Weight	40 (4.2%)	27 (2.7%)	62 (5.9%)	64 (5.8%)	192 (15.1%)
Drug data	12 (1.2%)	13 (1.3%)	33 (3.1%)	45 (4.1%)	191 (15.0%)

Table 21 Transplant follow-up data, 1 months

Variable	2012	2013	2014	2015	2016
Frequency	950	994	1034	1050	1256
Weight	23 (2.4%)	28 (2.8%)	54 (5.2%)	102 (9.7%)	198 (15.8%)
Serum creatinine	7 (0.7%)	17 (1.7%)	36 (3.5%)	49 (4.7%)	179 (14.3%)
Drug data	4 (0.4%)	9 (0.9%)	34 (3.3%)	38 (3.6%)	171 (13.6%)

Table 22 Transplant follow-up data, 2 months

Variable	2012	2013	2014	2015	2016
Frequency	914	1007	1009	1059	1203
Weight	37 (4.0%)	29 (2.9%)	64 (6.3%)	117 (11.0%)	227 (18.9%)
Serum creatinine	10 (1.1%)	17 (1.7%)	40 (4.0%)	46 (4.3%)	188 (15.6%)
Drug data	4 (0.4%)	9 (0.9%)	36 (3.6%)	37 (3.5%)	182 (15.1%)

Table 23 Transplant follow-up data, 3 months

Variable	2012	2013	2014	2015	2016
Frequency	915	993	1016	1052	1182
Weight	35 (3.8%)	34 (3.4%)	79 (7.8%)	130 (12.4%)	227 (19.2%)
Serum creatinine	14 (1.5%)	21 (2.1%)	48 (4.7%)	52 (4.9%)	169 (14.3%)
Drug data	5 (0.5%)	9 (0.9%)	44 (4.3%)	44 (4.2%)	164 (13.9%)

Table 24 Transplant follow-up data, 6 months

Variable	2012	2013	2014	2015	2016
Frequency	895	1015	982	982	1176
Weight	39 (4.4%)	40 (3.9%)	94 (9.6%)	149 (15.2%)	276 (23.5%)
Serum creatinine	24 (2.7%)	19 (1.9%)	50 (5.1%)	63 (6.4%)	198 (16.8%)
Drug data	6 (0.7%)	5 (0.5%)	47 (4.8%)	58 (5.9%)	195 (16.6%)

Table 25 Transplant follow-up data, 12 months

Variable	2012	2013	2014	2015	2016
Frequency	910	916	959	1003	1042
Weight	15 (1.6%)	44 (4.8%)	102 (10.6%)	143 (14.3%)	217 (20.8%)
Serum creatinine	10 (1.1%)	11 (1.2%)	35 (3.6%)	53 (5.3%)	163 (15.6%)
Drug data	2 (0.2%)	4 (0.4%)	37 (3.9%)	51 (5.1%)	153 (14.7%)

Table 26 Transplant follow-up data, 24 months

Variable	2012	2013	2014	2015	2016
Frequency	888	893	895	938	983
Weight	29 (3.3%)	42 (4.7%)	97 (10.8%)	121 (12.9%)	196 (19.9%)
Serum creatinine	20 (2.3%)	22 (2.5%)	29 (3.2%)	54 (5.8%)	127 (12.9%)
Drug data	2 (0.2%)	3 (0.3%)	35 (3.9%)	52 (5.5%)	120 (12.2%)

Table 27 Transplant follow-up data, 36 months

Variable	2012	2013	2014	2015	2016
Frequency	826	850	852	869	905
Weight	33 (4.0%)	38 (4.5%)	87 (10.2%)	124 (14.3%)	157 (17.3%)
Serum creatinine	14 (1.7%)	16 (1.9%)	30 (3.5%)	48 (5.5%)	111 (12.3%)
Drug data	4 (0.5%)	2 (0.2%)	36 (4.2%)	49 (5.6%)	111 (12.3%)

Table 28 Transplant follow-up data, 60 months

Variable	2012	2013	2014	2015	2016
Frequency	637	765	783	795	799
Weight	31 (4.9%)	28 (3.7%)	99 (12.6%)	127 (16.0%)	174 (21.8%)
Serum creatinine	14 (2.2%)	13 (1.7%)	35 (4.5%)	46 (5.8%)	115 (14.4%)
Drug data	3 (0.5%)	2 (0.3%)	42 (5.4%)	38 (4.8%)	109 (13.6%)

Table 29 Transplant follow-up data, 84 months

Variable	2012	2013	2014	2015	2016
Frequency	565	568	587	701	718
Weight	31 (5.5%)	34 (6.0%)	71 (12.1%)	90 (12.8%)	156 (21.7%)
Serum creatinine	22 (3.9%)	20 (3.5%)	24 (4.1%)	41 (5.8%)	105 (14.6%)
Drug data	0 (0.0%)	4 (0.7%)	28 (4.8%)	39 (5.6%)	93 (13.0%)

Table 30 Transplant follow-up data, 120 months

Variable	2012	2013	2014	2015	2016
Frequency	501	426	521	470	489
Weight	25 (5.0%)	26 (6.1%)	55 (10.6%)	60 (12.8%)	103 (21.1%)
Serum creatinine	16 (3.2%)	11 (2.6%)	15 (2.9%)	32 (6.8%)	67 (13.7%)
Drug data	2 (0.4%)	2 (0.5%)	3 (0.6%)	30 (6.4%)	59 (12.1%)

Table 31 Transplant follow-up data, 180 months

Variable	2012	2013	2014	2015	2016
Frequency	284	277	258	321	306
Weight	26 (9.2%)	25 (9.0%)	39 (15.1%)	46 (14.3%)	73 (23.9%)
Serum creatinine	17 (6.0%)	12 (4.3%)	17 (6.6%)	23 (7.2%)	53 (17.3%)
Drug data	5 (1.8%)	2 (0.7%)	14 (5.4%)	25 (7.8%)	50 (16.3%)

Table 32 Transplant follow-up data, 240 months

Variable	2012	2013	2014	2015	2016
Frequency	138	120	137	162	179
Weight	15 (10.9%)	9 (7.5%)	16 (11.7%)	26 (16.0%)	33 (18.4%)
Serum creatinine	6 (4.3%)	4 (3.3%)	8 (5.8%)	13 (8.0%)	21 (11.7%)
Drug data	0 (0.0%)	1 (0.8%)	7 (5.1%)	12 (7.4%)	22 (12.3%)

Table 33 Transplant follow-up data, 300 months

Variable	2012	2013	2014	2015	2016
Frequency	69	83	82	84	97
Weight	5 (7.2%)	6 (7.2%)	8 (9.8%)	14 (16.7%)	20 (20.6%)
Serum creatinine	3 (4.3%)	2 (2.4%)	3 (3.7%)	11 (13.1%)	12 (12.4%)
Drug data	0 (0.0%)	0 (0.0%)	3 (3.7%)	5 (6.0%)	11 (11.3%)

Table 34 Transplant follow-up data, 360 months

Variable	2012	2013	2014	2015	2016
Frequency	47	40	41	40	45
Weight	5 (10.6%)	3 (7.5%)	10 (24.4%)	10 (25.0%)	12 (26.7%)
Serum creatinine	1 (2.1%)	2 (5.0%)	4 (9.8%)	5 (12.5%)	8 (17.8%)
Drug data	0 (0.0%)	0 (0.0%)	4 (9.8%)	4 (10.0%)	9 (20.0%)

Table 35 Transplant follow-up data, 420 months

Variable	2012	2013	2014	2015	2016
Frequency	22	20	19	19	31
Weight	1 (4.5%)	2 (10.0%)	4 (21.1%)	5 (26.3%)	11 (35.5%)
Serum creatinine	1 (4.5%)	1 (5.0%)	2 (10.5%)	2 (10.5%)	8 (25.8%)
Drug data	0 (0.0%)	0 (0.0%)	4 (21.1%)	2 (10.5%)	8 (25.8%)

Table 36 Transplant follow-up data, 480 months

Variable	2012	2013	2014	2015	2016
Frequency	5	4	9	7	9
Weight	1 (20.0%)	1 (25.0%)	3 (33.3%)	1 (14.3%)	2 (22.2%)
Serum creatinine	1 (20.0%)	1 (25.0%)	2 (22.2%)	0 (0.0%)	1 (11.1%)
Drug data	0 (0.0%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	1 (11.1%)

Table 37 Transplant follow-up data, 540 months

Variable	2012	2013	2014	2015	2016
Frequency	0	2	2	5	6
Weight	-	2 (100.0%)	1 (50.0%)	3 (60.0%)	2 (33.3%)
Serum creatinine	-	2 (100.0%)	1 (50.0%)	1 (20.0%)	2 (33.3%)
Drug data	-	2 (100.0%)	2 (100.0%)	1 (20.0%)	2 (33.3%)

Table 38 Transplant follow-up data, 600 months

Variable	2012	2013	2014	2015	2016
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

Table 39 Paediatric assessment at entry

Variable	2012	2013	2014	2015	2016
Frequency	48	40	44	39	48
Height	18 (37.5%)	13 (32.5%)	3 (6.8%)	10 (25.6%)	25 (52.1%)
Weight	18 (37.5%)	12 (30.0%)	3 (6.8%)	10 (25.6%)	25 (52.1%)
Paediatric Assessment at end of each Survey	17 (35.4%)	14 (35.0%)	4 (9.1%)	12 (30.8%)	26 (54.2%)

Table 40 Paediatric assessment at survey

Variable	2012	2013	2014	2015	2016
Frequency	328	331	339	334	352
Height	36 (11.0%)	33 (10.0%)	32 (9.4%)	31 (9.3%)	41 (11.6%)
Weight	32 (9.8%)	27 (8.2%)	22 (6.5%)	26 (7.8%)	39 (11.1%)
Paediatric Assessment at end of each Survey	35 (10.7%)	26 (7.9%)	21 (6.2%)	29 (8.7%)	41 (11.6%)

Table 41 Parenthood data

Variable	2012	2013	2014	2015	2016
Frequency	70	65	70	74	48
Pregnancy outcome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.4%)	0 (0.0%)
Foetal outcome	7 (10.0%)	7 (10.8%)	1 (1.4%)	6 (8.1%)	12 (25.0%)
Neonatal survival	8 (11.4%)	6 (9.2%)	4 (5.7%)	8 (10.8%)	12 (25.0%)
Medical conditions acquired	4 (5.7%)	4 (6.2%)	1 (1.4%)	2 (2.7%)	3 (6.3%)

Table 42 Parenthood birthweight data

Variable	2012	2013	2014	2015	2016
Frequency	61	51	62	68	38
Weight at birth (gms)	20 (32.8%)	14 (27.5%)	15 (24.2%)	18 (26.5%)	7 (18.4%)

Table 43 Parenthood creatinine prior to conception

Variable	2012	2013	2014	2015	2016
Frequency	18	22	27	20	14
Creatinine prior to conception	3 (16.7%)	5 (22.7%)	2 (7.4%)	3 (15.0%)	2 (14.3%)

Table 44 Parenthood creatinine post delivery

Variable	2012	2013	2014	2015	2016
Frequency	16	21	27	19	11
Creatinine 3 months post delivery	2 (12.5%)	8 (38.1%)	4 (14.8%)	5 (26.3%)	2 (18.2%)

Table 45 Non-skin cancer data

Variable	2012	2013	2014	2015	2016
Frequency	628	622	576	541	392
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	12 (1.9%)	6 (1.0%)	11 (1.9%)	8 (1.5%)	9 (2.3%)
Cancer staging code	10 (1.6%)	8 (1.3%)	9 (1.6%)	18 (3.3%)	21 (5.4%)
Type 1st treatment	10 (1.6%)	10 (1.6%)	9 (1.6%)	23 (4.3%)	22 (5.6%)